Henry F. Vischer

The FDA-approved CDK4/6 inhibitor Abemaciclib is a potent agonist of the β-arrestin-biased atypical chemokine receptor ACKR3

This paper identifies abemaciclib, an FDA-approved CDK4/6 inhibitor, as a potent agonist of ACKR3, an atypical chemokine receptor, revealing its ability to modulate chemokine availability and receptor activity.

Inhibition of constitutive activity of the atypical chemokine receptor ACKR3 by the small-molecule inverse agonist VUF16840

This study characterizes VUF16840 as a selective inverse agonist of ACKR3 that inhibits constitutive and chemokine-induced signaling by stabilizing the inactive conformation of the receptor.

Design, synthesis and pharmacological characterization of the first photoswitchable small-molecule agonist for the Atypical Chemokine Receptor 3

This paper designs and characterizes the first photoswitchable small-molecule agonist for ACKR3, showing its selectivity and light-controlled activation properties.

Genetically encoded sensors for measuring histamine release both in vitro and in vivo

This paper develops genetically encoded sensors to measure histamine release in vitro and in vivo, showing high sensitivity and specificity for extracellular histamine detection.